ARCUS BIOSCIENCES INC (RCUS) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:RCUS - US03969F1093 - Common Stock
RCUS Key Statistics, Chart & Performance
The current stock price of RCUS is 21.3 USD. In the past month the price decreased by -15.27%. In the past year, price increased by 51.82%.
RCUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About RCUS
Company Profile
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 627 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Company Info
ARCUS BIOSCIENCES INC
3928 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Terry Rosen
Employees: 627
Phone: 15106946200
ARCUS BIOSCIENCES INC / RCUS FAQ
What does ARCUS BIOSCIENCES INC do?
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 627 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
What is the current price of RCUS stock?
The current stock price of RCUS is 21.3 USD. The price increased by 1.38% in the last trading session.
Does RCUS stock pay dividends?
RCUS does not pay a dividend.
What is the ChartMill rating of ARCUS BIOSCIENCES INC stock?
RCUS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for ARCUS BIOSCIENCES INC?
ARCUS BIOSCIENCES INC (RCUS) currently has 627 employees.
What is ARCUS BIOSCIENCES INC worth?
ARCUS BIOSCIENCES INC (RCUS) has a market capitalization of 2.91B USD. This makes RCUS a Mid Cap stock.
RCUS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RCUS. When comparing the yearly performance of all stocks, RCUS is one of the better performing stocks in the market, outperforming 90.9% of all stocks.
RCUS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCUS. RCUS has a bad profitability rating. Also its financial health evaluation is rather negative.
RCUS Financial Highlights
Over the last trailing twelve months RCUS reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS decreased by -9.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.01% | ||
| ROE | -78.21% | ||
| Debt/Equity | 0.22 |
RCUS Forecast & Estimates
18 analysts have analysed RCUS and the average price target is 32.74 USD. This implies a price increase of 53.72% is expected in the next year compared to the current price of 21.3.
For the next year, analysts expect an EPS growth of -15.04% and a revenue growth -5.62% for RCUS